192 related articles for article (PubMed ID: 15808955)
1. Molecular markers of prostate cancer outcome.
Quinn DI; Henshall SM; Sutherland RL
Eur J Cancer; 2005 Apr; 41(6):858-87. PubMed ID: 15808955
[TBL] [Abstract][Full Text] [Related]
2. Biomolecular markers of outcome prediction in prostate cancer.
Lopergolo A; Zaffaroni N
Cancer; 2009 Jul; 115(13 Suppl):3058-67. PubMed ID: 19544547
[TBL] [Abstract][Full Text] [Related]
3. Prognostic markers in prostate cancer.
Ross JS; Sheehan CE; Fisher HA; Kauffman RA; Dolen EM; Kallakury BV
Expert Rev Mol Diagn; 2002 Mar; 2(2):129-42. PubMed ID: 11962333
[TBL] [Abstract][Full Text] [Related]
4. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
5. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
Singhal S; Vachani A; Antin-Ozerkis D; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Jun; 11(11):3974-86. PubMed ID: 15930332
[TBL] [Abstract][Full Text] [Related]
8. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression.
Knudsen BS; Miranti CK
J Cell Biochem; 2006 Oct; 99(2):345-61. PubMed ID: 16676354
[TBL] [Abstract][Full Text] [Related]
9. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
Reddy GP; Barrack ER; Dou QP; Menon M; Pelley R; Sarkar FH; Sheng S
J Cell Biochem; 2006 Aug; 98(6):1408-23. PubMed ID: 16619263
[TBL] [Abstract][Full Text] [Related]
10. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses.
Voorzanger-Rousselot N; Garnero P
Cancer Treat Rev; 2007 May; 33(3):230-83. PubMed ID: 17433551
[TBL] [Abstract][Full Text] [Related]
11. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines.
Trojan L; Schaaf A; Steidler A; Haak M; Thalmann G; Knoll T; Gretz N; Alken P; Michel MS
Anticancer Res; 2005; 25(1A):183-91. PubMed ID: 15816537
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial androgen receptor targeted therapy for prostate cancer.
Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
D'Antonio JM; Ma C; Monzon FA; Pflug BR
Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review).
Wu J
Anticancer Res; 1996; 16(4B):2233-9. PubMed ID: 8694549
[TBL] [Abstract][Full Text] [Related]
15. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers in bladder cancer.
Shariat SF; Karam JA; Lerner SP
Curr Opin Urol; 2008 Jan; 18(1):1-8. PubMed ID: 18090481
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor decoy molecules block the growth of prostate cancer.
Quayle SN; Mawji NR; Wang J; Sadar MD
Proc Natl Acad Sci U S A; 2007 Jan; 104(4):1331-6. PubMed ID: 17227854
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
20. [Anti-apoptotic effect of the androgen receptor in human prostate cancer].
Shen FY; Li BY
Zhonghua Nan Ke Xue; 2007 Dec; 13(12):1121-4. PubMed ID: 18284065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
